Coherus Oncology (CHRS) Company Report

Coherus Oncology, Inc. announced a clinical supply agreement with Janssen Research & Development, LLC on February 4, 2026.
The agreement is for a Phase 1b clinical study to evaluate Coherus's investigational anti-CCR8 cytolytic monoclonal antibody, tagmokitug (CHS-114), in combination with Janssen's T-cell engaging bispecific antibody, pasritamig.
The study will focus on patients with metastatic castration-resistant prostate cancer (mCRPC).
Under the terms, Janssen will provide pasritamig, and Coherus will be the sponsor of the clinical trial, with both companies retaining all commercial rights to their respective compounds.

3 days ago

8-K

Coherus Oncology Provides Update on Transformation and Pipeline at JPMorgan Healthcare Conference

CHRS

M&A

New Projects/Investments

Guidance Update

Coherus Oncology has transformed into an innovative oncology company, completing the divestiture of its biosimilar business for approximately $800 million, which included paying down $480 million in debt and adding $250 million to the balance sheet.
The company's cornerstone therapy, Loqtorzi, a next-generation PD-1, is a revenue generator for nasopharyngeal cancer and a revenue multiplier in combination with other agents. Loqtorzi's estimated revenues doubled from $19 million in 2024 to $40.8 million in 2025, with a target of $150-$200 million by mid-2028.
Key pipeline assets include CHS-114, a best-in-class CCR8 Treg depleter, and Casdozokitug, a first-in-class IL-27 antagonist, both with global rights.
Coherus anticipates a data-rich year in 2026, with significant readouts expected mid-year across its portfolio, including for CHS-114 in various cancers and Casdozokitug in first-line HCC.
The company emphasizes its deal-making proficiency through acquisitions, divestitures, and future collaborations, particularly for ex-U.S. licensing of CHS-114 to help offset long-term development costs.

Jan 13, 2026, 6:30 PM

Transcript

Coherus Oncology Updates on Transformation, Pipeline, and Financial Strategy

CHRS

M&A

New Projects/Investments

Guidance Update

Coherus Oncology has completed its transformation into an innovative oncology company by divesting its biosimilar business, including Cimerli for approximately $175 million and Udenyca for $558 million, totaling around $800 million. This enabled the company to pay down $480 million in debt and add $250 million to its balance sheet, providing about two years of cash for clinical studies.
LOQTORZI, a cornerstone product, is estimated to have doubled revenues from $19 million in 2024 to $40.8 million in 2025. The company is confident in achieving its target of $150 million-$200 million by mid-2028, driven by systematic sales growth and strong market understanding.
The company is advancing its oncology pipeline with tegmokitug, a best-in-class CCR8 Treg depleter, and casdozokitug, a first-in-class IL-27 antagonist, both acquired from Surface Oncology. Coherus anticipates a data-rich year in 2026, with significant readouts for both assets, particularly in gastric, esophageal, colorectal, and head and neck cancers for tegmokitug, and first-line HCC for casdozokitug.
Coherus plans to pursue ex-U.S. licensing deals for tegmokitug in 2026 to offset development costs and leverage its broad applicability with other therapies.

Jan 13, 2026, 6:30 PM

Transcript

Coherus Oncology Provides Update on Transformation, Pipeline, and 2026 Data Readouts

CHRS

M&A

New Projects/Investments

Guidance Update

Coherus Oncology has completed its transformation into an innovative oncology company by divesting its biosimilar business for approximately $800 million, which enabled the company to pay down $480 million in debt and add $250 million to its balance sheet.
The company's oncology pipeline, including Loqtorzi (PD-1), CHS-114 (CCR8 Treg depleter), and Casdozokitug (IL-27 antagonist), represents a $29 billion market opportunity.
Loqtorzi achieved 10%-15% quarterly revenue growth in 2025, with estimated revenues of $40.8 million for 2025 (up from $19 million in 2024), and is on track to reach $150-$200 million by mid-2028.
Mid-2026 is expected to be a data-rich year, with readouts for CHS-114 across multiple cancer indications and for Casdozokitug in first-line hepatocellular carcinoma (HCC), which previously demonstrated a 38% overall response rate and 17% complete response rate.

Jan 13, 2026, 6:30 PM

Transcript

Coherus Details Immuno-Oncology Pipeline and Key Drug Developments

CHRS

New Projects/Investments

Product Launch

Coherus (CHRS) has pivoted its focus from biosimilars to a broad immuno-oncology pipeline, holding global rights to its assets.
The company's first-in-class anti-IL27 antibody, Castozza, in a triple combination with Atizo-Bev, demonstrated a 38% overall response rate and 17% complete response rate in first-line hepatocellular carcinoma (HCC) patients, with an encouraging safety profile compared to Atizo-Bev alone.
Initial data for the ongoing Castozza triple combination study in HCC is anticipated around mid-2026, with plans for a larger phase 2/3 adaptive design study to follow.
Coherus is also developing Tagmukitug (formerly CHS-114), a differentiated CCR8 antibody designed to selectively deplete intratumoral T regulatory cells in various solid tumors, including head and neck, gastric, cervical, colorectal, lung, ovarian, breast, and pancreatic cancers.

Dec 17, 2025, 6:30 PM

Transcript

Coherus Oncology Provides Pipeline Update and 2026 Outlook

CHRS

New Projects/Investments

Guidance Update

Revenue Acceleration/Inflection

Coherus Oncology has strategically refocused on its innovative oncology pipeline following the full divestiture of its biosimilar pipeline in 2025.
The Castozza Keytech program, in combination with Atizo-Bev for first-line hepatocellular carcinoma (HCC), demonstrated an overall response rate of 38% and a complete response rate of 17% in 30 subjects, significantly improving on historical Atizo-Bev rates of 30% ORR and 8% CR.
Initial data from the ongoing Phase 2 study for the Castozza triplet (Castozza-Tori-Bev vs. Tori-Bev alone) in first-line HCC is anticipated around mid-2026.
Toripalimab (LOQTORZI) is projected to achieve peak sales of $150 million-$200 million by 2028, with recent data showing it nearly doubled median overall survival in the JUPITER study from 33 months to 65 months.
Coherus anticipates 2026 to be a data-rich year with potential for significant patient benefit from its promising pipeline.

Dec 17, 2025, 6:30 PM

Transcript

Coherus Oncology Highlights Pipeline Progress and Future Data Readouts

CHRS

New Projects/Investments

Product Launch

Guidance Update

Coherus Oncology, having divested its biosimilar pipeline in 2025, is now strategically focused on oncology and expects 2026 to be a "data-rich year" with multiple potential proof-of-concept data readouts.
The Casdozokitug-Atezo-Bev triplet demonstrated a 38% overall response rate (ORR) and a 17% complete response (CR) rate in first-line hepatocellular carcinoma (HCC), an improvement over the historical 30% ORR and 8% CR rate of Atezo-Bev alone, with favorable tolerability.
Initial data for the Phase II study of Casdozokitug in combination with Toripalimab and Bevacizumab in HCC is anticipated around mid-2026, with plans for a larger Phase II/III adaptive design study.
Toripalimab (Loqtorzi) is projected to achieve peak sales of $150 million-$200 million by 2028, and extended follow-up data from the JUPITER study demonstrated it nearly doubled median overall survival from 33 months to 65 months when combined with Gem-Cis.
Tagmokitug, a cytolytic antibody targeting CCR8, is differentiated by its selective binding, enhanced potency, and distinct binding mechanism.

Dec 17, 2025, 6:30 PM

Transcript

Coherus Oncology Highlights Strategic Repositioning and Pipeline Progress

CHRS

M&A

Product Launch

New Projects/Investments

Coherus Oncology (CHRS) has strategically repositioned as an innovative oncology company, divesting its biosimilar franchise for nearly $800 million and acquiring Surface Oncology for $65 million in stock, which enabled the company to pay off $480 million in debt.
The company's commercial product, LOQTORZI, launched in early 2024 for nasopharyngeal cancer, is showing 10-15% growth and is expected to reach $150-$200 million by mid-2028.
Key pipeline assets include CHS-114, a highly selective Treg depleter with promising anti-tumor activity in head and neck cancer, and casdozokitug, an anti-IL-27 that achieved a 38% overall response rate and 17% complete response rate in liver patients, approximately double the standard of care.
Coherus is actively seeking partnerships and ex-US licensing for its pipeline to drive deals, validate assets, provide upfronts, and spread the costs of pivotal trials.

Nov 18, 2025, 10:30 AM

Transcript

Coherus Oncology Highlights Oncology Pipeline and Market Opportunity

CHRS

Product Launch

New Projects/Investments

M&A

Coherus Oncology presented its value proposition, emphasizing its foundational PD-1 product LOQTORZI, and pipeline assets CHS-114 and casdozokitug.
LOQTORZI, approved for nasopharyngeal cancer, is expected to reach $150-$200 million in revenue by mid-2028.
The pipeline asset casdozokitug demonstrated a 38% overall response rate and a 17% complete response rate in liver cancer patients.
The company's combined pipeline addresses an estimated $30 billion market opportunity in the U.S..
Coherus Oncology recently divested its biosimilar franchise, paying off $480 million in debt, and acquired Surface Oncology for approximately $65 million in stock.

Nov 18, 2025, 10:30 AM

Transcript

Coherus Oncology CEO Highlights Pipeline Progress and Market Strategy at Jefferies Conference

CHRS

Product Launch

New Projects/Investments

Coherus Oncology's CEO, Dennis Lanfear, outlined the company's "drugs, data, and deals" value proposition, emphasizing its repositioning to innovative oncology following the divestiture of biosimilar assets, which generated almost $800 million and paid off $480 million in debt.
The company's commercial product, LOQTORZI (toripalimab), approved for nasopharyngeal cancer, is projected to fully saturate its market by mid-2028 and achieve revenues approaching the midpoint of the $150-$200 million range.
Key pipeline assets include CHS-114, a highly selective Treg depleter with ongoing studies in colorectal, gastric, and head and neck cancers, and casdozokitug (anti-IL-27) for liver and lung cancers.
Early data for casdozokitug in liver cancer demonstrated a 38% overall response rate and a 17% complete response rate, which is approximately double the standard of care.
The combined pipeline targets an estimated $30 billion market opportunity in the U.S. alone.